This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases examined real-world evidence from the Global aHUS Registry showing that switching from eculizumab to ravulizumab is safe and effective for atypical hemolytic uremic syndrome (aHUS) patients. Among 60 participants who made this transition, ravulizumab showed a favorable safety profile with minimal treatment-related side effects. Disease markers remained stable after switching, and no patients required dialysis or kidney transplantation during ravulizumab treatment. Both medications block the C5 protein to prevent complement system overactivity, but ravulizumab requires less frequent dosing.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘Global aHUS Registry Analysis of Patients Switching to Ravulizumab From Eculizumab’ and was published in Kidney International Reports.

Visit ISN using the link to read the original article.